PhRMA Cries Foul On FDA Drug Labeling Guidance
Recent guidance from the U.S. Food and Drug Administration improperly said drugs that receive accelerated approval should have prominent labeling disclaimers about uncertainty surrounding their effectiveness, potentially scaring off patients and...To view the full article, register now.
Already a subscriber? Click here to view full article